Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas

Emad Elquza; Hani M. Babiker; Krisha J. Howell; Andrew I. Kovoor; Thomas David Brown; Hitendra Patel; Steven A. Malangone; Mitesh J Borad; Tomislav Dragovich

doi:10.3109/07357907.2015.1108426

Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas

Emad Elquza, Hani M. Babiker, Krisha J. Howell, Andrew I. Kovoor, Thomas David Brown, Hitendra Patel, Steven A. Malangone, Mitesh J Borad, Tomislav Dragovich

Hematology/Oncology

Research output: Contribution to journal › Article

Abstract

ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m².

Original language	English (US)
Pages (from-to)	57-63
Number of pages	7
Journal	Cancer Investigation
Volume	34
Issue number	2
DOIs	https://doi.org/10.3109/07357907.2015.1108426
State	Published - Feb 7 2016

Keywords

cisplatin
gastroesophageal carcinoma
Pemetrexed
radiation

ASJC Scopus subject areas

Medicine(all)
Oncology
Cancer Research

Access to Document

10.3109/07357907.2015.1108426

Fingerprint Dive into the research topics of 'Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas'. Together they form a unique fingerprint.

Cite this

Elquza, E., Babiker, H. M., Howell, K. J., Kovoor, A. I., Brown, T. D., Patel, H., Malangone, S. A., Borad, M. J., & Dragovich, T. (2016). Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. Cancer Investigation, 34(2), 57-63. https://doi.org/10.3109/07357907.2015.1108426

Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. / Elquza, Emad; Babiker, Hani M.; Howell, Krisha J.; Kovoor, Andrew I.; Brown, Thomas David; Patel, Hitendra; Malangone, Steven A.; Borad, Mitesh J; Dragovich, Tomislav.

In: Cancer Investigation, Vol. 34, No. 2, 07.02.2016, p. 57-63.

Research output: Contribution to journal › Article

Elquza, E, Babiker, HM, Howell, KJ, Kovoor, AI, Brown, TD, Patel, H, Malangone, SA, Borad, MJ & Dragovich, T 2016, 'Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas', Cancer Investigation, vol. 34, no. 2, pp. 57-63. https://doi.org/10.3109/07357907.2015.1108426

Elquza, Emad ; Babiker, Hani M. ; Howell, Krisha J. ; Kovoor, Andrew I. ; Brown, Thomas David ; Patel, Hitendra ; Malangone, Steven A. ; Borad, Mitesh J ; Dragovich, Tomislav. / Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. In: Cancer Investigation. 2016 ; Vol. 34, No. 2. pp. 57-63.

@article{ce26be1e3e57419db682a61f456364b8,

title = "Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas",

abstract = "ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.",

keywords = "cisplatin, gastroesophageal carcinoma, Pemetrexed, radiation",

author = "Emad Elquza and Babiker, {Hani M.} and Howell, {Krisha J.} and Kovoor, {Andrew I.} and Brown, {Thomas David} and Hitendra Patel and Malangone, {Steven A.} and Borad, {Mitesh J} and Tomislav Dragovich",

year = "2016",

month = feb,

day = "7",

doi = "10.3109/07357907.2015.1108426",

language = "English (US)",

volume = "34",

pages = "57--63",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas

AU - Elquza, Emad

AU - Babiker, Hani M.

AU - Howell, Krisha J.

AU - Kovoor, Andrew I.

AU - Brown, Thomas David

AU - Patel, Hitendra

AU - Malangone, Steven A.

AU - Borad, Mitesh J

AU - Dragovich, Tomislav

PY - 2016/2/7

Y1 - 2016/2/7

N2 - ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.

AB - ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.

KW - cisplatin

KW - gastroesophageal carcinoma

KW - Pemetrexed

KW - radiation

UR - http://www.scopus.com/inward/record.url?scp=84977463111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977463111&partnerID=8YFLogxK

U2 - 10.3109/07357907.2015.1108426

DO - 10.3109/07357907.2015.1108426

M3 - Article

C2 - 26810581

AN - SCOPUS:84977463111

VL - 34

SP - 57

EP - 63

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 2

ER -